Crystal structure of tofacitinib dihydrogen citrate (Xeljanz ® ), (C 16 H 21 N 6 O)(H 2 C 6 H 5 O 7 )
Source abstract
Abstract
The crystal structure of tofacitinib dihydrogen citrate (tofacitinib citrate) has been solved and refined using synchrotron X-ray powder diffraction data, and optimized using density functional techniques. Tofacitinib dihydrogen citrate crystallizes in space group P 2 1 2 1 2 1 (#19) with a = 5.91113(1), b = 12.93131(3), c = 30.43499(7) Å, V = 2326.411(6) Å 3 , and Z = 4. The crystal structure consists of corrugated layers perpendicular to the c -axis. Within the layers, cation⋯anion and anion⋯anion hydrogen bonds link the fragments into a two-dimensional network parallel to the ab -plane. Between the layers, there are only van der Waals contacts. A terminal carboxylic acid group in the citrate anion forms a strong charge-assisted hydrogen bond to the ionized central carboxylate group. The other carboxylic acid acts as a donor to the carbonyl group of the cation. The citrate hydroxy group forms an intramolecular charge-assisted hydrogen bond to the ionized central carboxylate. Two protonated nitrogen atoms in the cation act as donors to the ionized central carboxylate of the anion. These hydrogen bonds form a ring with the graph set symbol R2,2(8) . The powder pattern has been submitted to ICDD ® for inclusion in the Powder Diffraction File™ (PDF ® ).
Source: crossref · Quality: baseline
Research context
OpenAlex topics: X-ray Diffraction in Crystallography · Crystallography and molecular interactions · Polymer Synthesis and Characterization
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (33)
Show source-provided references
1. 10.1063/1.46788210.1063/1.467882 ↗
2. 10.1002/qua.2465810.1002/qua.24658 ↗
3. Bravais · 1866
4. 10.1107/S002188981300353110.1107/S0021889813003531 ↗
5. Flanagan, M. E. and Li, Z. J. (2002). “Novel crystalline compound,” European Patent EP 1,451,192 B1.
6. Lei, X. , Peng, J. , and Guo, Z. (2015). “Tofacitinib citrate,” International Patent Application WO 2015/051738 A1.
7. 10.1107/S002188981101462210.1107/S0021889811014622 ↗
8. Open babel: an open chemical toolbox
9. Blumenkopf, T. A. , Flanagan, M. E. , and Munchhof, M. J. (2001). “Pyrrolo[2,3-d]pyrimidine compounds,” International Patent Application WO 01/42246 A2.
10. 10.1107/S160057671901409210.1107/S1600576719014092 ↗
11. 10.1063/1.296926010.1063/1.2969260 ↗
12. 10.1017/S088571561400051710.1017/S0885715614000517 ↗
13. 10.1107/S205252061600395410.1107/S2052520616003954 ↗
14. 2020
15. 10.1007/BF0054909610.1007/BF00549096 ↗
16. 10.1107/S002188981301311310.1107/S0021889813013113 ↗
17. A new law of crystal morphology extending the law of bravais
18. 10.1017/S088571561900081210.1017/S0885715619000812 ↗
19. Turner, M. J. , McKinnon, J. J. , Wolff, S. K. , Grimwood, D. J. , Spackman, P. R. , Jayatilaka, D. , and Spackman, M. A. (2017). CrystalExplorer17 (University of Western Australia). Available at: http://hirshfeldsurface.net.
20. Etudes sur la loi de bravais
21. 10.1002/anie.19951555110.1002/anie.199515551 ↗
22. 10.1107/S090904950801843810.1107/S0909049508018438 ↗
23. Wilcox, G. E. , Koecher, C. , Vries, T. , Flanagan, M. E. , and Munchhof, M. J. (2002). “Optical resolution of (1-benzyl-4-methylpiperidin-3-yl)-methylamine and the use thereof for the preparation of pyrrolo-2,3-pyrimidine derivatives as protein kinases inhibitors,” International Patent Application WO 02/096909 A1.
24. 10.1107/S205252061800233010.1107/S2052520618002330 ↗
25. Silk Scientific (2013). UN-SCAN-IT 7.0 (Silk Scientific Corporation, Orem, UT).
26. 10.1017/S088571561800082910.1017/S0885715618000829 ↗
27. MDI (2020). JADE Pro version 7.8 (Computer software), Materials Data, Livermore, CA, USA.
28. 10.1107/S010876819901508610.1107/S0108768199015086 ↗
29. 10.1107/S205252061402290210.1107/S2052520614022902 ↗
30. 10.1107/S002188980201523610.1107/S0021889802015236 ↗
31. 10.1021/ar00172a00510.1021/ar00172a005 ↗
32. 10.1021/ci049780b10.1021/ci049780b ↗
33. Wavefunction, Inc. (2020). Spartan ‘18 Version 1.4.5, Wavefunction Inc., 18401 Von Karman Ave., Suite 370, Irvine, CA 92612.